Introduction
Head and neck/oral squamous cell carcinomas (HNOSCCs)representthesixthmostcommontype of cancers worldwide [1] . Despite tremendous improvements in treatment by surgery, radiotherapy, and chemotherapy over the past decades, the prognosisforpatientswithHNOSCCshasnotchanged. HNOSCC is a disease that can arise in various anatomic locations, including the oral cavity, tongue, pharynx,andlarynx.Oraltonguesquamouscellcarcinoma(OTSCC)isoneofthemostcommontypesof HNOSCCandissignificantlymoreaggressivethan other forms of HNOSCC in terms of local invasion andspread.Althoughsomeofthemolecularevents underlyingthiscomplexdiseasehavebeenidentified, thepathwaysinvolvedinthedevelopmentandprogression of squamous cell carcinoma of the tongue arestillpoorlyunderstood [2, 3, 4, 5] .
Protein tyrosine kinase 7 (PTK7), also known as colon carcinoma kinase-4 (CCK-4), is a member of areceptortyrosinekinase(RTK)familythatisconserved among human, Drosophila, Japanese puffer fish, Hydra, and chicken. PTK7 is an evolutionarily conserved transmembrane protein containing seven immunoglobulin domains, a transmembrane domain, and a catalytically inactive kinase domain [6, 7, 8] .PTK7isaWntco-receptorandanimportantregulatorofplanarcellpolarity(PCP)anddirectionalcellmotilityinembryogenesisandvertebrate development [9, 10, 11] . The PCP signaling pathways control cell mobility and cellular polarity, re-sultinginmodificationofthecytoskeleton.DeregulationofPCPcancausevariouspathologicdisorders, including cancer. Well-known regulators of PCP include Wnt ligands and Frizzled receptors, which activatetheDishevelledadaptorattheplasmamembraneandinitiatetheso-calledWntpathway,either initscanonical(β-catenin-dependent)ornon-canonical(β-catenin-independent)form [12, 13] .
Overexpression of PTK7 has been documented in several human cancers, including colon, gastric, and esophageal cancer and acute myelogenous leukemia. Overexpression of PTK7 is associated with anadverseclinicaloutcomeincolorectalcancer,and high expression of PTK7 is significantly associated withtumorinvasivenessandpoorprognosisinintrahepaticcholangiocarcinoma.Interestingly,wepreviouslyfoundthattheexpressionofPTK7proteinwas decreasedinepithelialovariancarcinomaswithpoor prognosis [14] .
Inthisstudy,weexaminedtheexpressionofPTK7 proteininasetofformalin-fixedparaffin-embedded tissue samples of OTSCC using a PTK7-specific polyclonalantibodyandanalyzedtherelationshipbetweentheexpressionofPTK7andclinicopathologic parametersandoverallsurvivalofpatients.
Material and methods

Patients and clinicopathologic variables
Thestudycohortconsistedof64consecutivepa-tients with OTSCC who underwent surgery from 2001 to 2011 in Nanjing Stomatological Hospital, China.Patientagerangedfrom20to85years(mean age57years,SD=11.7),and44patientshadhigh-gradediseaseand20hadlow-gradedisease.Noneof the patients received preoperative chemotherapy or radiationtherapy.Allhematoxylinandeosin-stained slideswerereviewedbytwoexperiencedpathologists to verify the diagnosis, histologic grade, and stage. HPV infection was detected by the PCR method. The patients were followed up until April 2012. Therecordsofpatientswhowerealiveatfollow-up orwhodidnotdieofthediseasewereconsideredto becensored.Thisinvestigationwasperformedafter obtaining approval from the Ethics Committee of Nanjing Stomatological Hospital, China. Informed consentwasobtainedfromeachpatient.
Immunohistochemistry
Sections from surgical specimens were fixed in 10% formalin and embedded in paraffin. Immunohistochemical staining was carried out according to astandardmethod.Briefly,each4-µmtissuesection was deparaffinized and rehydrated through a graded ethanol series. The sections were autoclaved in 10mMcitratebuffer(pH6.0)at120°Cfor2minfor antigenretrievalandthencooledto30°Candwashed with phosphate-buffered saline (PBS, pH 7.3). Endogenous peroxidase were quenched with aqueous 3%H 2 O 2 for10minandthesectionswerewashed withPBSandincubatedat4°Covernightwithpri-maryrabbitpolyclonalanti-PTK7antibody(1:500 dilution; Abgent, San Diego, CA, USA). The sectionswereincubatedwithsecondaryantibody(Dako REAL EnVision Detection System, Dako, UK) for 20minatroomtemperature.Aftercounterstaining, theslideswerewashedwithPBS,dehydrated,cleared in xylene and mounted in neutral balsam. Primary antibody was replaced with antibody diluent for negativecontrols.Samplesofnormalfallopiantubes withknownpositivitywereusedaspositiveexternal controls.
PTK7 staining was independently evaluated for immunoreactivity according to the scoring criteria below by two pathologists who were double-blinded to clinical data. Immunoreactivity score was determined according to the intensity of cytoplasmic staining where 0 = no staining, 1+ = weak, 2+=moderate,and3+=strong.Theexpression ofPTK7wasdefinedasnegative(0and1+)orpositive(2+and3+).
Follow-up
Follow-up data were collected from the patients' recordsandtelephoneinterviewsofpatients.Overall survival(OS)wasdefinedasthetimefromsurgeryto thedateofdeath.Themedianfollow-uptimewas37 months(range:7-115months).
Statistical analysis
Theχ 2 testwasusedtoassesstherelationshipbetweenPTK7proteinexpressionandclinicopatholog-icparameters.Survivalcurveswereconstructedusing the Kaplan-Meier method, and differences between the curves were compared using the log-rank test. P-values<0.05(two-sided)wereconsideredstatisticallysignificant.Allanalyseswereperformedusing SPSSsoftware(version16.0,Chicago,IL,USA). 
Results
PTK7 expression in OTSCC and its correlation with clinicopathologic features
Association between PTK7 expression and overall survival in patients
Usingthefollow-updataofthe64patientsincon-junctionwiththeresultsfromPTK7IHCstainingex-periments,weshowedthatpatientswithhighPTK7 expression (2+ and 3+) had a poor overall survival(OS)comparedwithpatientswithnegative(0)or weakPTK7expression(1+)(p =0.058, Fig.3 ).
Discussion
PTK7 expression has been evaluated in various humancancersand,interestingly,wasfoundtobeincreasedinsomecancertypesanddecreasedinother types. Lhoumeau et al. examined PTK7 expression by immunohistochemistry in tumoral tissue and matchednormalmucosaeusingaclinicallyannotated tissue microarray (TMA) from 192 consecutive cases of colorectal cancer (CRC) [15] . The relationshipbetweenexpressionofPTK7andclinicopatho-logicfeaturesandoutcomeofpatientswasanalyzed. PTK7wassignificantlyupregulatedin34%ofCRC tissues compared with matched healthy mucosa. PTK7 overexpression was significantly associated with reduced metastasis-free survival in patients with non-metastatic disease. They further showed thatPTK7depletionbyspecificshRNAintwoCRC celllines(HCT116andHCT15)reducedcellmigrationbutdidnotaffectcellproliferationorresistance to drugs. Downregulation of PTK7 in a xenograft mousemodelledtoreducedtumorgrowth,whereasintroductionofPTK7intoPTK7-negativecancer cells led to increased metastatic events in vivo. The authorsconcludedthatPTK7isapotentialprognos-ticbiomarkerandanoveltherapeutictargetinCRC.
The expression and role of PTK7 in intrahepatic cholangiocarcinoma (ICC) were investigated by Jin et al. [16] . They found that cells with high PTK7 expression exhibited higher proliferation, DNA [17] . PTK7wassignificantlyupregulatedintumortissue samples and its expression was inversely correlated with overall survival. In vivo knockdown of PTK7 inhibitedproliferation,survival,woundhealing,and invasionofESCCcells. AlloftheabovestudiesindicatethatPTK7hasan oncogenicroleinhumancancersandmightbeused asaprognosticmarkerforcancerpatients.
However, in other types of human cancer PTK7 wasrevealedtofunctionasatumorsuppressor.Easty et al.studiedtheexpressionofPTK7inmelanomacell linesandbiopsies [18] .PTK7mRNAwasdetectedin only54%ofmelanomacelllinesand20%ofmela-noma biopsies, and loss of expression of PTK7 was observedinmetastaticmelanomas.Linet al.assessed theexpressionofPTK7in201gastriccancersamples usingimmunohistochemistry [19] .PTK7expression wasdetectedin56.7%ofgastriccancerpatients,and was significantly associated with well-differentiated tumorstatusandfavorableoverallsurvivalanddisease-freesurvival.WepreviouslyreportedthatPTK7 expressionisdecreasedinepithelialovariancarcinoma with poor prognosis [14] . Expression of PTK7 was detected in 92% of normal fallopian tube epitheliumand45%ofepithelialovariantumortissues. ExpressionofPTK7wassignificantlyassociatedwith clinical stage and metastasis in ovarian borderline serous tumors. Patients with negative expression of PTK7 had a poor outcome. These results indicate thatPTK7maybeatumorsuppressorinovarianse-rouscarcinoma.
Inthepresentstudy,wefoundthathighexpressionofPTK7wasmoreoftendetectedinoraltongue squamous cell carcinoma patients with lymph node metastasis, advanced TNM stage, and a poorly differentiated tumor. Patients with high expression of PTK7hadpooroverallsurvival.Toourknowledge, thisisthefirstreport oftheexpression ofPTK7in oraltonguesquamouscellcarcinoma.Carcinomaof thetongueisachallengingdisease;ithasapoorprognosisatanadvancedstage,andeventumorsthatare discoveredatanearlystagecanhaveafatalcourse. According to the National Comprehensive Cancer Network(NCCN)GuidelinesforCanceroftheOral Cavity (2016, version 2), stage I carcinoma of the tongueistreatedwithwedgeexcisiononly,whereas moreadvancedtumors(stagesII-IV)aretreatedwith preoperative irradiation followed by more extensive surgery. Nguyen et al. reported their experience in providing effective and well-tolerated 0-7-21 palliative radiotherapy to patients with head and neck cancers [20] .However,amongstageItonguecarcinomasthereisasubgroupoftumorsthatareprone tolymphnodemetastasisandlocalrecurrence.Ifthis more aggressive tumor behavior could be predicted,patientswhoareatincreasedriskoflymphnode metastasis and recurrence could be subjected to extendedtreatment,whereasthosewithlessaggressive carcinomas could be spared the morbidity associated with such treatment. Many attempts have been madetopredicttheoutcomefortonguecarcinomas throughhistopathologicstudiesandmolecularbiologyanalysis [21, 22, 23, 24] .
Receptortyrosinekinasesarekeymediatorsofsignalingpathwaysincells,whichhavebeenshownto beinvolvedinregulationofnormalcellularprocesses andalsoplayanimportantroleinthedevelopment, progression and spread of cancers. Recently, some of the receptor tyrosine kinases including HER2, EGFR, and VEGFR have become key targets for cancer therapy. PTK7 is a member of the receptor tyrosine kinases. Our findings suggest that PTK7 playsanoncogenicroleinoraltonguesquamouscell carcinoma.TheinhibitionofPTK7expressioncould beanewtherapeutictargetfororaltonguesquamous cellcarcinoma. 
Conclusions
In summary, our data indicate that high expressionofPTK7wassignificantlyassociatedwithlymph node metastasis, advanced TNM stage, poor differentiationstatus,andpooroverallsurvivalofpatients withoralOTSCC.PTK7proteinexpressionwasas-sociatedwithprognosisofsquamouscellcarcinoma ofthetongueandmayserveasaprognosticmarker andapotentialtherapeutictarget. 
This investigation was
